레비티라세탐(Levetiracetam) 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 판매 채널별(직접 판매, 간접 판매), 최종 용도별(간질, 뇌전증 지속증, 보조 요법, 기타), 지역별, 경쟁별(2020-2030년)

Levetiracetam Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel (Direct, Indirect), By End Use (Epilepsy, Status Epilepticus, Adjunctive Therapy, Others), By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,197,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,574,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,017,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

레베티라세탐 세계 시장은 2024년에 15억 9,144만 달러로 평가되며, 2030년에는 31억 3,883만 달러에 달할 것으로 예상되며, 예측 기간 동안 10.48%의 CAGR로 성장할 것으로 예상됩니다.

2세대 항간질제(AED)인 레베티라세탐은 우수한 약동학적 특성, 최소한의 약물 상호작용, 다양한 발작 유형에 대한 효과로 의료 전문가들 사이에서 신뢰받고 있습니다. 전 세계적으로 약 5,000만 명이 앓고 있는 간질 유병률의 증가가 수요를 견인하는 주요 요인으로 작용하고 있습니다. 또한, 레베티라세탐은 간질 이외의 질환(신경인성 통증, 불안 등)의 치료에서 레베티라세탐의 역할이 확대됨에 따라 그 용도가 확대되고 있습니다. 서방형 제제 및 정맥 투여 제제의 혁신으로 환자의 복약 순응도와 치료 결과가 지속적으로 개선되고 있습니다. 약물전달을 최적화하고 부작용을 최소화하기 위한 지속적인 연구개발을 통해 레베티라세탐은 시장 성장세를 이어갈 준비를 하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	15억 9,144만 달러
시장 규모 : 2030년	31억 3,883만 달러
CAGR : 2025-2030년	10.48%
급성장 부문	다이렉트
최대 시장	북미

시장 촉진요인

헬스케어 산업의 성장

주요 시장 과제

신흥국 시장에서의 가격 침식

주요 시장 동향

신경질환 유병률 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 레비티라세탐 시장에 미치는 영향

제5장 세계의 레비티라세탐 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 판매 채널별(직접, 간접)
  • 용도별(간질, 뇌전증 지속증, 보조 요법, 기타)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 레비티라세탐 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 레비티라세탐 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 레비티라세탐 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 레비티라세탐 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 레비티라세탐 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 레비티라세탐 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Devi Chemscience Private Limited
• Medikament Pharma
• HINDUSTAN SILICHEM PRIVATE LIMITED
• Venkata Narayana Active Ingredients Private Limited
• Andhra Medi Pharma india Pvt. Ltd.
• Bhavani Interchem Pvt Ltd
• Honour Lab Limited
• Ramis Laboratories Private Limited
• Lupin Limited
• Hetero Labs Limited

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

ksm

영문 목차

영문목차

The Global Levetiracetam Market was valued at USD 1,591.44 Million in 2024 and is projected to reach USD 3,138.83 Million by 2030, growing at a CAGR of 10.48% during the forecast period. Levetiracetam, a second-generation antiepileptic drug (AED), is highly regarded for its favorable pharmacokinetic attributes, minimal drug interactions, and effectiveness across various seizure types, making it a trusted option among medical professionals. The rising global incidence of epilepsy, which impacts around 50 million individuals worldwide, is a major factor driving demand. Additionally, levetiracetam's expanding role in treating conditions beyond epilepsy-such as neuropathic pain and anxiety-has broadened its application. Innovations in extended-release and intravenous formulations continue to improve patient adherence and therapeutic outcomes. With ongoing R&D aimed at optimizing drug delivery and minimizing side effects, levetiracetam is poised to maintain strong market momentum.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 1,591.44 Million
Market Size 2030	USD 3,138.83 Million
CAGR 2025-2030	10.48%
Fastest Growing Segment	Direct
Largest Market	North America

Key Market Drivers

Growth in Healthcare Industry

The robust expansion of the global healthcare sector, driven by increased access to care, rising investment, and technological advancements, is a key growth driver for the levetiracetam market. In developed nations, healthcare spending accounts for a significant share of GDP, such as the USD 4.3 trillion spent in the U.S. in 2021. As the demand for effective neurological treatments grows-especially for chronic conditions like epilepsy-levetiracetam continues to gain prominence for its efficacy and well-tolerated profile. Epilepsy, a noncommunicable neurological condition affecting approximately 50 million people globally, remains prevalent across all age groups. Nearly 80% of those affected live in low- and middle-income regions, where expanding healthcare access is increasing the reach of antiepileptic medications. With early diagnosis and proper treatment, up to 70% of epilepsy patients can achieve seizure control, further bolstering the need for reliable drugs such as levetiracetam in emerging markets.

Key Market Challenges

Price Erosion in Developing Markets

Price erosion due to the proliferation of generic alternatives is a significant challenge impacting the global levetiracetam market, especially in developing regions. Following the expiry of patents for branded versions like Keppra, numerous generic formulations have entered the market, intensifying competition and driving prices downward. In cost-sensitive areas such as Asia, Latin America, and parts of Africa, healthcare systems often prioritize affordability, pushing manufacturers toward low-cost options. While this enhances treatment accessibility, it exerts pressure on profit margins for pharmaceutical companies, particularly those with higher production and regulatory compliance costs. For multinational firms, maintaining brand loyalty and perceived quality becomes increasingly difficult in markets where pricing dictates purchasing decisions.

Key Market Trends

Rising Prevalence of Neurological Disorders

The global rise in neurological disorders is significantly influencing demand for antiepileptic drugs like levetiracetam. Neurological conditions now affect over 3 billion people-approximately 43% of the global population-with common contributors including stroke, dementia, and epilepsy. The growing burden of these disorders across both developed and developing nations is spurring increased pharmaceutical activity. Levetiracetam, due to its broad-spectrum efficacy and favorable safety profile, is increasingly adopted as a primary treatment for various seizure types. Additionally, aging populations, improved diagnostics, and lifestyle factors are driving the prevalence of neurological illnesses. As a result, levetiracetam continues to gain traction as a versatile and dependable therapeutic option in neurology.

Key Market Players

• Devi Chemscience Private Limited
• Medikament Pharma
• HINDUSTAN SILICHEM PRIVATE LIMITED
• Venkata Narayana Active Ingredients Private Limited
• Andhra Medi Pharma India Pvt. Ltd.
• Bhavani Interchem Pvt Ltd
• Honour Lab Limited
• Ramis Laboratories Private Limited
• Lupin Limited
• Hetero Labs Limited

Report Scope

In this report, the Global Levetiracetam Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levetiracetam Market, By Sales Channel:

• Direct
• Indirect

Levetiracetam Market, By End Use:

• Epilepsy
• Status Epilepticus
• Adjunctive Therapy
• Others

Levetiracetam Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levetiracetam Market.

Available Customizations

Global Levetiracetam Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Levetiracetam Market

5. Global Levetiracetam Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Epilepsy, Status Epilepticus, Adjunctive Therapy, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Levetiracetam Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Levetiracetam Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Levetiracetam Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Levetiracetam Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Levetiracetam Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Levetiracetam Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Levetiracetam Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Levetiracetam Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Levetiracetam Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Levetiracetam Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Levetiracetam Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Levetiracetam Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Levetiracetam Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Levetiracetam Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Levetiracetam Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Levetiracetam Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Levetiracetam Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Levetiracetam Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Levetiracetam Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Levetiracetam Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Levetiracetam Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Levetiracetam Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Levetiracetam Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Levetiracetam Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Levetiracetam Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Devi Chemscience Private Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Medikament Pharma
• 15.3. HINDUSTAN SILICHEM PRIVATE LIMITED
• 15.4. Venkata Narayana Active Ingredients Private Limited
• 15.5. Andhra Medi Pharma india Pvt. Ltd.
• 15.6. Bhavani Interchem Pvt Ltd
• 15.7. Honour Lab Limited
• 15.8. Ramis Laboratories Private Limited
• 15.9. Lupin Limited
• 15.10. Hetero Labs Limited

16. Strategic Recommendations

17. About Us & Disclaimer